Tetracycline Capsules Faq
Q: What are the therapeutic indications for Tetracycline Capsules?
A: Tetracycline is a broad-spectrum bacteriostatic antibiotic indicated for the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, Chlamydia, Mycoplasma, Rickettsiae, and Spirochetes. Common clinical indications include severe acne vulgaris, respiratory tract infections, pelvic inflammatory disease, brucellosis, psittacosis, trachoma, and cholera, as well as an alternative therapy for syphilis and anthrax in penicillin-allergic patients.
Q: What is the mechanism of action of Tetracycline Hydrochloride?
A: Tetracycline reversibly binds to the 30S ribosomal subunit of susceptible microorganisms, preventing the access of aminoacyl-tRNA to the ribosomal acceptor (A) site. This blocks bacterial protein synthesis, arresting microbial growth and replication.
Q: What commercial strengths and pharmacopeial standards are available?
A: Tetracycline Hydrochloride Hard Gelatin Capsules are supplied in standard strengths of 250 mg and 500 mg, manufactured in strict accordance with BP, USP, Ph. Eur., Ph. Int., and IP monographs.
Q: What regulatory dossiers and technical documents are provided for country registration?
A: Comprehensive regulatory packages are available in CTD and ACTD formats (Modules 1–5), supported by WHO-GMP certification, Certificate of Pharmaceutical Product (COPP), batch-specific Certificates of Analysis (COA), Method of Analysis (MOA), Method Validation, Process Validation protocols, and TSE/BSE-free gelatin capsule shell certification.
Q: What stability study data is available to support international registration?
A: Finished batches are supported by accelerated testing (40°C ± 2°C / 75% RH ± 5% RH) and long-term real-time stability data (30°C ± 2°C / 75% RH ± 5% RH) under ICH guidelines, validated for shelf-life stability in Zone II, Zone IVa, and Zone IVb (hot and humid tropical climates).
Q: What primary and secondary packaging options are offered for commercial export?
A: Packaging configurations include moisture-barrier Alu-Alu blister packs, PVC/PVDC-Alu blister strips (such as 10×10 and 10×10×10 carton packs), and amber or opaque HDPE containers (100s, 500s, and 1,000s) fitted with induction foil seals, desiccants, and child-resistant/screw caps.
Q: What is the standard commercial Minimum Order Quantity (MOQ) and production turnaround?
A: The standard commercial MOQ for export-branded and customized contract packaging is 100,000 to 200,000 capsules per strength. Standard production lead time is 45 to 60 days following confirmed regulatory packaging artwork sign-off and commercial trade/payment clearance.
Q: Can you accommodate contract manufacturing (CDMO) and OEM private labeling?
A: Yes, contract manufacturing (CDMO), toll manufacturing, and private labeling services are supported. Services include custom two-tone capsule shell coloration, radial/axial capsule imprint branding, destination-specific multilingual carton localization, and GS1 2D datamatrix serialization.
Q: What are the shelf-life and ambient storage recommendations?
A: Finished capsules possess a 24- to 36-month shelf life. Store below 25°C in a dry place protected from light and moisture (as degraded, expired tetracyclines can cause Fanconi-like renal syndrome). International dispatches utilize rapid air cargo or temperature-monitored sea freight (15–25°C reefers) with container desiccants.
Q: How can international buyers procure registration samples and working standards?
A: Packaged commercial samples, empty dummy cartons, active working standards, and batch COAs are dispatched internationally via air courier upon receipt of a valid Drug Import Permit, Test License, or formal commercial Letter of Intent (LOI).